Annual report pursuant to Section 13 and 15(d)

Balance Sheets

v2.4.0.6
Balance Sheets (USD $)
Sep. 30, 2012
Sep. 30, 2011
Balance Sheets    
Cash $ 2,632,413 $ 469,786
Prepaid expenses 218,242 37,611
Grant receivable    179,358
Other current assets    5,000
Total Current Assets 2,850,655 691,755
EQUIPMENT, net 43,111 19,164
Patent costs, net 623,654 701,927
TOTAL ASSETS 3,517,420 1,412,846
Accounts payable and accrued expenses 300,462 301,055
Notes payable 22,037  
Derivative liabilities 768,696 5,893,544
Total Current Liabilities 1,091,195 6,194,599
TOTAL LIABILITIES 1,091,195 6,194,599
Preferred stock, Series B; 6,000,000 shares authorized, at $0.0001 par value, 5,583,336 and 5,583,336 shares issued and outstanding, respectively 558 558
Common stock; 180,000,000 shares authorized, at $0.0001 par value, 47,258,686 and 39,702,580 shares issued and outstanding, respectively 4,726 3,970
Additional paid-in capital 30,963,228 22,289,231
Stock subscription receivable (11,891)   
Accumulated deficit (21,628,748) (21,628,748)
Deficit accumulated during the development stage (6,901,648) (5,446,764)
Total Stockholders' Equity (Deficit) 2,426,225 (4,781,753)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 3,517,420 $ 1,412,846